Liver directed therapy: treatments for colorectal cancer metastasis
What is liver directed therapy?
Colorectal cancer can spread to other parts of your body through your blood or lymphatic system. The liver is the most common site of metastasis in patients with colorectal cancer, due to the blood supply that exists between the large intestine and the liver.
While liver metastasis can be very challenging to stop, there are options to consider for treatment.
Surgery can play an important role in treating liver metastasis for many patients. However, not everyone is a candidate for liver surgery.
There are a number of therapies that use chemotherapy, HAI therapy, ablation, radiation, cryotherapy, heat, and other approaches to reduce or remove liver metastases.
Because liver directed therapies are localized and target just the tumor, much of the surrounding tissue is spared. Many of these therapies are minimally invasive and have a short recovery time.
Approved liver directed therapies
Learn more about liver directed therapy
CRCtalks: Liver directed therapies for mCRCTop resources
Treatment for KRAS G12C-mutated metastatic CRC approved by FDA
The U.S. Food and Drug Administration has approved sotorasib in combination with panitumumab for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer.
Watch session videos from AllyCon 2024
Watch videos of two major general sessions from AllyCon 2024, the Alliance's patient support conference, which took place in Miami Beach in December.
Krazati approved for previously treated KRASG12C colorectal cancer
The treatment option is for patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC) who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.